- Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions - http://eyedocnews.com -
Regeneron’s Eylea: A Game Changer for Treatment of Macular Degeneration?
Posted By Dr. Ari Weitzner On August 22, 2012 @ 5:39 am In Industry News,Macular Degeneration,Retina | Comments Disabled
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) began selling Eylea late last year [1] for treatment of wet macular degeneration.
Recently, the American Journal of Ophthalmology published a review of the medical literature and pertinent Internet postings combined with analysis of key studies with expert opinion regarding the use of Eylea (a/k/a aflibercept) for the treatment of wet AMD.
The authors concluded that Eylea promises to deliver excellent visual outcomes for wet age-related macular degeneration patients while undergoing fewer injections compared with Lucentis (a/k/a ranibizumab). With a wholesale cost of $1850 per dose, the cost per patient with Eylea treatment promises to be lower than with Lucentis.
Click here [2] for access to the abstract.
Article printed from Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions: http://eyedocnews.com
URL to article: http://eyedocnews.com/006864-regenerons-eylea-a-game-changer-for-treatment-of-macular-degeneration/
URLs in this post:
[1] began selling Eylea late last year: http://eyedocnews.com/006301-regeneron-announces-fda-approval-of-eylea%e2%84%a2-aflibercept-injection-for-wet-age-related-macular-degeneration/
[2] Click here: http://www.ajo.com/article/S0002-9394%2812%2900330-3/abstract
Click here to print.
Copyright © 2008 Eye Doc Talk. All rights reserved.